Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial.
Summary
In a 99-patient, double-blind randomized trial, both niosomal 2% TXA/2% niacinamide and conventional 5% TXA/4% niacinamide creams achieved melanin index and mMASI reductions comparable to 4% hydroquinone over 3 months. Adverse reactions and relapse were observed in the hydroquinone group, suggesting TXA/NCA formulations as safer alternatives with equivalent efficacy.
Key Findings
- Both TXA/NCA formulations matched 4% hydroquinone in reducing melanin index and mMASI over 3 months.
- Hydroquinone group experienced adverse reactions and relapse; TXA/NCA groups had a more favorable safety profile.
- Quality of life improved across all groups during treatment.
Clinical Implications
TXA/niacinamide creams can be considered first-line or maintenance therapy for melasma, especially in patients intolerant to hydroquinone or at risk of adverse events/relapse.
Why It Matters
Provides high-quality comparative evidence supporting TXA/niacinamide as a hydroquinone-sparing option for melasma with fewer adverse effects, addressing a key safety limitation of HQ.
Limitations
- Single trial with 3-month follow-up; long-term durability and relapse rates beyond treatment are unknown
- Single-center design and formulation-specific results may limit generalizability
Future Directions
Head-to-head multicenter RCTs with longer follow-up to assess sustained remission, relapse after cessation, and optimal maintenance strategies; inclusion of objective imaging and pigment biomarkers.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized, double-blind clinical trial with active comparator across three arms.
- Study Design
- OTHER